The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem

For Immediate ReleaseChicago, IL – December 5, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen Inc. AMGN, Eaton Corp. plc ETN, Sony Group Corp. SONY, iMage Technologies, Inc. MITQ and Enzo Biochem, Inc. ENZ.Here are highlights from Wednesday’s Analyst Blog:Top Stock Reports for Amgen, Eaton and Enzo BiochemThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc., Eaton Corp. plc and Sony Group Corp., as well as two micro-cap stocks, Moving iMage Technologies, Inc. and Enzo Biochem. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Amgen’s shares have underperformed the Zacks Medical – Biomedical and Genetics industry over the last six months (-9.4% vs. -2.0%). The Zacks analyst believes that increased pricing headwinds and competitive pressure are hurting sales of many products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras pose potential threat.However, Evenity, Repatha, Prolia, Tavneos and Tezspire, are driving sales exponentially. The addition of Horizon products boosted revenue growth in the first half of the year. Amgen also has some key pipeline assets in obesity and inflammation, which have a large market opportunity.(You can read the full research report on Amgen here >>>)Eaton’s shares have outperformed the Zacks Manufacturing - Electronics industry over the past year (+65.7% vs. +33.9%). The Zacks analyst believes that the company benefits from research and development work and is aided by rising demand from the new AI data center. Eaton is expanding via acquisitions and strategy to manufacture in the region of its end market has helped the company to reduce expenses.Yet, Eaton’s global operations expose it to unpredictable currency translation, cyber security threats, changes in tax rates and security breaches, which might impact operations. The shortage of raw materials and supplier insolvencies might impact production and operations.(You can read the full research report on Eaton here >>>)Shares of Sony have outperformed the Zacks Audio Video Production industry over the past year (+18.4% vs. +13.0%). Per the Zacks analyst, steady growth across the G&NS, Music and I&SS segments has been a tailwind for Sony. The G&NS unit is gaining from favorable forex impact, higher sales from network services (PlayStation Plus) and rising sales of non-first-party titles.However, Sony’s performance is affected by reduced hardware sales, forex volatility and intense competition across major product categories. Continued slowdown across the financial services business and lower series deliveries in Television Productions have also ailed.(You can read the full research report on Sony here >>>)Moving iMage’s shares have underperformed the Zacks Technology Services industry over the last six months (-35.5% vs. +43.7%). The Zacks analyst believes that supply chain disruptions, competition from OTT platforms and regulatory compliance costs have continued to ail the company. Hollywood strikes earlier this year impacted demand for its products.Yet, its significant contract win with Alamo Drafthouse Cinema and expansion into high-margin SaaS and subscription-based products like MiTranslator and CineQC show great promise. Also, diversifying into live entertainment and eSports markets mitigates cinema industry cyclicality.(You can read the full research report on Moving iMage here >>>)Enzo’s shares have underperformed the Zacks Medical – Biomedical and Genetics industry over the past year (-13.7% vs. +1.0%). The Zacks analyst believes that persistent net losses, high operating costs, the exit from clinical labs reducing revenue streams and competitive pressures pose risks for the company. Addressing legal expenses are also crucial for sustained profitability.Yet, Enzo’s strategic pivot toward becoming a dedicated life sciences tools manufacturer has been effectively executed and is a major plus. Its broad and deep intellectual property (IP) portfolio, with patent coverage across vital enabling technologies also positions the company as a leader in innovation.(You can read the full research report on Enzo here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Eaton Corporation, PLC (ETN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report Moving iMage Technologies, Inc. (MITQ): Get Free ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks